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INTERPRETATION OF BLOODSPOT 1 7 4 -HYDROXYPROGES-TEROKE LEVELS I N TERM AND PRETERM NEONATES
Plasma l 7 d -Hydroxyprogesterone can vary considerably i n t h e f i r s t few days of l i f e . Bloodspot 17d-hydroxyprogesterone, plasma c o r t i s o l , plasma sodium and urinary 17M-hydroxyprortesterone, c o r t i s o l , sodium and c r e a t i n i n e l e v e l s were determined i n 24 term and 31 preterm i n f a n t s on t h e t h i r d , e i~h t h and fourteenth day of l i f e . Preterm i n f a n t s , whether 'well' o r ' s i c k ' had s i~n i f i c s n t l y r a i s e d bloodspot 174-hydroxyprop;esterone l e v e l s (up t o 158 nmol/l) compared with those found i n term s i c k o r well i n f a n t s (up t o 18.8 nmol/l).
Urinary 17.4-hydroxyproeesterone/creatinine r a t i o s were a l s o hieher i n preterm i n f a n t s . Plasma c o r t i s o l r e s u l t s showed s i m i l a r ranges f o r term and pre-term i n f a n t s , and bloodspot 1 7 d -hydroxyproaesterone/ plasma c o r t i s o l r a t i o s f o r day 3 specimens c o r r e l a t e d with t h e degree of prematurity. These r e s u l t s may be due e i t h e r t o immature enzyme systems i n t h e preterm baby o r t o an excess of r e l a t e d s t e r o i d s cross-reactinp; i n t h e 1 7 d -hydroxyprop;esterone assay. W e propose t h e use of two d i s t i n c t upper l i m i t s of normal of 20 nmol/l (term i n f a n t s ) and up t o XX)nmol/l (preterm i n f a n t s ) f o r t h e i n t e r p r e t a t i o n of bloodspot 17d-hydroxypro~esterone l e v e l s a t t h e end of t h e f i r s t week of l i f e . The aim o f p r e n a t a l treatment o f CAH is prevention o f v i r i l iz a t i o n o f f a n a l e f e t u s e s with 21 hydroxylase d e f i c i e n c y (21 adef.). '&XI mothers a t r i s k f o r CAH were f o l l m e d during pregnancy, according to the plan: treatment as e a r l y a s p o s s i b l e w i t h decadron 1 mg per day -transaMminai chorion v i l l u s biopsy (at week 11) t o determine t h e sex -amniocentesis ( a t week 17) t o est a b l i s h (HIA t y p e s and s t e r o i d s ) i f the f e t u s is a f f e c t e d -cont i n u e d treatnwt to b i r t h in a f f e c t e d girls. Case 1 (JIA) were t r e a t e d f r m 9 d s o f pregnancy. The f e t u s turned o u t to be a boy, and treatment was stopped. At b i r t h he had no s i g n s o f CAH (normal 17 Cel-progesterone (17 OHP), androstenedione (&one), t e s t o s t e r o n e , cortisol, A m , r e n i n ) . Case 2 ( W ) was treated and s t u d i e d according t o the p l a n and the f e t u s was a g i r l , amniocentesis was p e r f o r m 4 and shm& raised v a l u e s f o r 17 OHP (30 m 1 / 1 ) , Pdione (4 m l / l ) . She was HIAi d e n t i c a l to the a f f e c t e d sister (A3B7/A3B47) and the treatment w i t h decadron (discontinued 5 days before the amniocentesis) was continued to birth. ?he adrenal function o f the mother was totall y suppressed (urw cortisol < 20 m 1 / 2 4 h ) , b u t normal a f t e r b i r t h . Study o f the g i r l a t day 1 and day 3 showed raised 17 OHP (172-123 m l / l ) , .3 m l / l ) , r e n i n (530-1824 pGU/ ml) , ACI' H (320 ~g / m l ) and low aldosterone (1 6-29 ng/lco ml) . The external g e n i t a l i a showed a d e f i n i t i v e lesser v i r i l i z a t i o n (Prader s t a g e 1-2) by canparison w i t h the sister (h:ader s t a g e 4 ) . Marginal s a l t l o s s and hyperreninemia were previously r eported i n p a t i e n t s with 11-OHD on glucocorticoid replacement (JCEM 58:384, 1984) . To evaluate t h e need f o r mineralocorticold therapy, 7 p a t i e n t s with 11-OHD, 5-14 y e a r s of age, were subjected t o 3 consecutive schedules of treatment: 1 ) 1 mg/day dexamethasone (OEX) f o r 4 days, 2) 17 mg/m2/day hydrocortisone a c e t a t e (HC) f o r 4 days, and 3 ) HC and 0.1-0.2 mg/day 9a-fluorohydrocortisone (9aF) The l a t t e r combination suppressed PRA, produced b e t t e r c o n t r o l of t h e pituitary-adrenal a x i s and enabled t h e use of a physiol o g i c dose of HC. PRA needs t o be monitored in 11-OHD p a t i e n t s ; when i t i s elevated, mineralocorticoid replacement i s indicated.
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CONGENITAL VIRILIZING ADRENALHYPERPLASIA (CVAH) DUE TO 21 HYDROXYLASE DEFICIENCY, RESULTS OF THERAPY \VITH CYPROTERONE ACETATE (CA).
Results obtained from t e n prepubertal p a t i e n t s ( 6 g i r l s , 4 boys) s u f f e r i n g of CVAH were compared over 12-41 months periods before and over 14-52 months periods durinq CA therapy (63 2 21 (SD)mg/m2/day). A t t h e beginning of treatment with CA, growth parameters were a s follow : chronological (Ch) ages 5 t o 10 years, heights (H) 102.5 2 9.2% of normal H f o r Ch ages, bone 12.24 ' .72 mg/m2/day, during CA treatment, ( p < .05), 17 hydroxyprogesterone (170HP) and t e s t o s t e r o n e (T) plasma l e v e l s decreased from 62 t 9.8 t o 22.7 ' 7 ( p < .01) and from .42 f .07 t o .17 f .03 ( p < .05) respectively. When compared t o normal values f o r B ages, most plasma DHA values were normal before (9110) and during (7/10), most A4 androstenedione (AqA) values were elevated before (9110) and normal (9110) during CA treatment, while A4A/T r a t i o s increased s i g n i f i c a n t l y from 3.7 ' .32 t o 6.4 f .A6 ( p < .01). I n conclusion, CA appears t o be of i n t e r e s t i n t h e treatment of prepubertal p a t i e n t s with CVAH. The antiandrogenic e f f e c t is demonst r a t e d by t h e improvement of bone maturation, t h e i n h i b i t i o n of ACTH production by t h e decreases i n 170HP l e v e l s . I n a d d i t i o n t h e r e is evidence of a decrease i n t h e conversion r a t e s of adrenal androgens t o testosterone. ~.~i~a r t i n o -n a r d~f ~.~t o n e r T ~.~'~o n n e l l T M. One of t h e goals of glucocorticoid therapy i n c l a ss i c a l CAH i s t o s u r e s s e i c e s s andro en roduction t o revent remature epiehyse!P c l o s u r e and resuytdne s h o r t s t a f u r e . ~R i s r e t r o s p e c t i v e s t d y was conducted t o determine i f t h e f i n d l height (FH) of 45 a d u l t p a t i e n t s ( p t s ) with CAH was inf!uenced by t h e c l i n i c a l v a r i a n t (salt-wdsting (SW) v.; simple v i r i l i z i n g (SV)), age diagnosis was made and treatment i n i t iated ard t h e degree of hormonal control. bood o r poor hormonal conti01 were determined from levels of 24 hr urinary 17-KS serum ~4 -a n d r o s t e n e d i one (~4 -A ) acd 17-OHP. The p a t i e n t wa; assigned t o t h e cdtegory of good c o~i t r o l i f n~ore than 50% of d a i l y urinary 17-KS o r serum ~4 -A were normel f o r age (meantZSD o r i f 50% of t h e serum 17-OHP l e v e l s were < 1000 ngidl. Ail others were assigned t o t h e poor control category; :i pts had i n s u f f i c i e n t d a t a f o r assig~lment. Final height was compared t o t h e mid-parental height (MPH t o t h e normal popul a t i o n . and t o 5 never t r e a t e d pts with h C A H The !dean f i n a l H t f o r a l l male p a t i e n t s was 163.2 cm ark f o r a l l female p a t i e n t s was 153.3 cm. Conclusion: The adult height of 3 never t r e a t e d females was not a i t t e r e n t from any t r e a t e d fe:41ales, whether i n yood o r poor c o n t r o l , S W o r SV, o r t r e a t e d e a r l y o r l a t e . Among t h e t r e a t e d males, height wa\ not d i f f e r e n t whether they were in good o r poor c o n t r o l , S W o r SV, o r t r e a t d e a r l y o r l a t e . Although t h e 2 never t r e a t e d inales a r e s h o r t e r , t h a n t r e a t e d illales t h e small number of ts recludes s t a t i s t i c a l analysis.
hi mean f i n a l heights o ! a17 pts were s i n i f i c a n t l y l e s s than t h e mean heights of males and females i n t z e normal population.
